Site icon Autoimmune Encephalitis

THE HERD November 2018~1st ed

image 6 1 - THE HERD November 2018~1st ed


Selected Highlighted News in the field of Autoimmune

Encephalitis November 2018 1st edition

In this IssueMayo Clinic develops new testing for MOG and ApQ4 antibodies and discovered two new antibodies in 2017 – GFAP and MAP1b. Slideshow presentation of Drs. Graus and Dalmau’s recent overview of AE- A ‘must’/’go to’ resource. Updated information on Autoimmune Epilepsy including reference chart. The Lancet Summit November 15-18th Barcelona, Spain

Mayo Clinic Develops New Testing for antibodies in

Autoimmune Encephalitis-

MOG and AQP4 


Mayo Clinic now offers a comprehensive central nervous system demyelinating disease evaluation that includes both MOG antibody (the first-in-the-U.S. test to detect antibodies to the MOG protein) and AQP4 antibody tests. Mayo studies indicate MOG disease is twice as common as AQP4- IgG-associated diseases and affects about 1 million people.  There is no overlap between the two antibodies in an individual patient. The combination of the two tests—AQP4 and MOG antibodies—allows for the most comprehensive evaluation for patients recently diagnosed with demyelinating diseases. 

In 2017, Mayo discovered 2 new new biomarkers for Autoimmune Encephalitis: GFAP and MAP1b antibodies

GET YOUR LEARNING ON! IAES believes this Research will be One of the Most Highly Cited by Neurologists in the Field

IAES wants all of our members to better understand antibody-mediated Autoimmune Encephalitis so you become stronger advocates and self- advocates. Education is Power! It helps you reach recovery and your best possible outcomes.

We highly suggest you spend time with Dr. Graus and Dr. Dalmau and view this  OUTSTANDING slide show that reviews their recently published work from March 2018 in the New England Journal of Medicine.  

Antibody mediated encephalitis ppt

 Autoimmune Epilepsy 

You have heard us discuss Autoimmune Epilepsy since Mayo Clinic developed an Epilepsy Autoimmune Evaluation in 2014. For an epilepsy to meet this classification, evidence of autoimmune-mediated central nervous system (CNS) inflammation is required. Treatment of immunologic epilepsy includes targeted immunotherapies in combination with antiepileptic drugs. These are the same antibodies in AE (see referenced chart above). This article seeks to provide a basic clinical approach to diagnosis and treatment.

The Lancet Summit: Inflammation and Immunity in Disorders of the Brain and Mind

Barcelona, Spain

November 15-17, 2018

International Autoimmune Encephalitis Society (IAES) is a Family/Patient centered organization that assists members from getting a diagnosis through to recovery and the many challenges experienced in their journey.


Driven by the knowledge that “Education is Power”, International Autoimmune Encephalitis Society manages an educational support group for patients diagnosed with Autoimmune Encephalitis and their loved ones, empowering them to be strong self-advocates and advocates that will lead them to best outcomes and recovery. We are the premiere organization leading in these vital roles.  Raising awareness of Autoimmune Encephalitis across the many specialties of medicine that come in contact with these disorders and with the general public to ensure a timely and accurate diagnosis resulting in an aggressive treatment plan for best outcomes.

“Empowering victims of Autoimmune Encephalitis and their caregivers through Support and Education”.

Exit mobile version